"This observation is procedural in nature and the corrective and preventive actions for this observation will be submitted to the USFDA within the stipulated period," Gland Pharma stated. The observation issued is neither a repeated observation nor related to data integrity, it added.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Hp0m5dX
via IFTTT
0 comments:
Post a Comment